An interventional study of Active tDCS and Sham tDCS in Catatonia, sponsored by Centre Hospitalier St Anne. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.
Sponsored by Centre Hospitalier St Anne · Not applicable, Interventional, and Treatment
Nearly 10% of people hospitalized in psychiatry have a catatonic syndrome. The treatment of this syndrome is based on lorazepam and electro-convulsive therapy (ECT) in drug-resistant forms. ECT is the reference therapy, very effective in catatonia, but remain difficult to access due to the technical platform required for their realization, leading to delays in the implementation of the treatment responsible for an increase in the morbidity and mortality of catatonia. In this context, a new therapeutic tool available in the treatment of drug-resistant catatonia would improve the prognosis of catatonia. Transcranial direct current stimulation (tDCS) is an alternative, non-invasive brain stimulation technique that does not require anesthesia, and inexpensive and has been shown to be effective in depression and schizophrenia. A series of clinical cases suggests its potential efficacy in catatonia. Our objective is to evaluate the efficacy of tDCS in catatonia in a clinical trial.
Catatonia is a pathology combining affective, motor, behavioural and neuro-vegetative symptoms. Nearly 10% of people hospitalized in psychiatry have a catatonic syndrome. However, it is a severe disorder with a potentially lethal course.
For the treatment of catatonia, lorazepam is effective in most cases, with the percentage of responding patients varying between 70 and 80 per cent, according to the literature. Catatonic episodes resistant to lorazepam are usually associated with chronic catatonia as part of a neurodevelopmental disorder. Genetic abnormalities are often found in these forms of catatonia.
Electroconvulsive therapy (ECT) should be considered for any catatonic episode that is resistant to lorazepam. It is also indicated when a rapid effect must be obtained in life-threatening situations (e.g. malignant catatonia) or when the underlying pathology requires this treatment. Its efficacy is considered excellent, with response rates ranging from 59% to 100%, including when patients have not responded to lorazepam.
There are several limitations to ECT treatment for catatonia:
Among neuromodulation techniques, the promising alternative approaches are transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS).
Transcranial direct current stimulation (tDCS) is a non-invasive electrical brain stimulation that does not require anaesthesia. The tDCS is based on applying a low direct electrical current (typically less than 20 volts) via two electrodes placed on the scalp. The electric current is applied to the anode (positive electrode) and then flows to the cathode (negative electrode). The electrodes, surrounded by sponges soaked in a saline solution, are positioned at the level of the scalp according to the international 10-20 placement system or, more rarely, according to the MRI-guided neuronavigation system. The device is easily transportable and does not require a specific technical platform.
The present study, randomized versus placebo, aims to test the efficacy of tDCS stimulation on catatonic-resistant syndrome.
22 studies on the registry are indexed under Catatonia; 10 are open to participants now.
This study's planned enrollment of 70 is above the median of 63 across 14 interventional studies indexed under Catatonia.
Browse Catatonia studies →Centre Hospitalier St Anne is the lead sponsor of 101 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active transcranial Direct Current Stimulation (tDCS): Stimulation of 2mA for 20 minutes
Device: Active tDCS
Sham transcranial Direct Current Stimulation (tDCS): Effective stimulation of 2.5 mA for 30 seconds, then the stimulation stops. The complete session lasts 20 minutes, with 19 minutes and 30 seconds without stimulation.
Device: Sham tDCS
* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system). * Cathode opposite the left temporoparietal junction (between T3 and P3). * The stimulation level is 2mA for 20 minutes. * Sessions are held twice daily on working days (with a minimum of 3 hours between sessions). Twenty sessions will be carried out, two sessions per consecutive working day.
Also known as: Active transcranial Direct Current Stimulation
* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system). * Cathode opposite the left temporoparietal junction (between T3 and P3). * Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation. * Sessions are held twice daily on working days (with a minimum of 3 hours between sessions). Twenty sessions will be carried out, two sessions per consecutive working day.
Also known as: Sham transcranial Direct Current Stimulation
Bush-Francis Catatonia Rating Scale (BFCRS)
The BFCRS is a comprehensive tool for diagnosing and assessing the severity of catatonic syndrome. The BFCRS was devised by Bush, Fink, Petrides, Dowling and Francis in 1996. This scale consists of the assessment of 23 symptoms, scored from 0 to 3. The total score of the BFCRS is the sum of the responses to the 23 items (minimum 0 - maximum 69). High scores reflect a severe disorder. Improvement is defined by a 30% decrease in BFCRS scores after 5 days of treatment (10 tDCS sessions)
Time frame: Day 6
Bush-Francis Catatonia Rating Scale (BFCRS)
The BFCRS is a comprehensive tool for diagnosing and assessing the severity of catatonic syndrome. The BFCRS was devised by Bush, Fink, Petrides, Dowling and Francis in 1996. This scale consists of the assessment of 23 symptoms, scored from 0 to 3. The total score of the BFCRS is the sum of the responses to the 23 items (minimum 0 - maximum 69). High scores reflect a severe disorder. The treatment response is assessed as the absolute reduction of the BCRF score after 20 sessions.
Time frame: Day 14
Effectiveness of active tDCS vs sham: patients in remission after 20 sessions
Percentage of patients who no longer fulfil the DSM-5 criteria for catatonic syndrome. This criterion was assessed at each session between V1 and V14.
Time frame: every day from Day 1 to Day 14
Lorazepam treatment (mg/die)
Lorazepam daily administration in mg/die
Time frame: At baseline then every day from Day 1 to Day 14
Percentage of patients requiring electroconvulsive therapy (ECT)
Percentage of patients requiring electroconvulsive therapy (ECT) during the evaluation period (active vs shamm tDCS)
Time frame: Every day from Day 1 to Day 14
Occurrence of catatonic syndrome complications
Pulmonary embolism confirmed by angioscan, transfer to intensive care, pressure sores, inhalation pneumonia requiring antibiotic therapy, death.
Time frame: Every day from Day 1 to Day 14
To assess the effectiveness of tDCS by comparing changes over time in psychiatric symptomatology: Montgomery-Asberg depression scale (MADRS score)
The Montgomery-Asberg depression scale (MADRS ) is a 10 -item scale used to assess the severity of depression. High scores reflect a severe disorder (score range 0-60).
Time frame: At baseline, then at Day 1, Day 6, and from Day 11 to Day 14
To assess the effectiveness of tDCS by comparing changes over time in psychiatric symptomatology: schizophrenia: . Positive and Negative Syndrome Scale (PANSS score)
PANSS (Positive and Negative Syndrome Scale): is a 30-item scale widely used in schizophrenia research to assess positive and negative psychotic dimensions. The PANSS is composed of 3 subscales: Positive Scale, Negative Scale, and General Psychopathology Scale. Each subscale is rated with 1 to 7 points ranging from absent to extreme. The range for the Positive and Negative Scales is 7-49, and the range for the General Psychopathology Scale is 16-112. The total PANSS score is simply the sum of the sub scales. In addition to these measures, a Composite Scale is scored by subtracting the negative score from the positive score. This yields a bipolar index that ranges from -42 to +42, which is essentially a difference score reflecting the degree of predominance of one syndrome in relation to the other.
Time frame: At baseline, then at Day 1, Day 6, and from Day 11 to Day 14
To assess the effectiveness of tDCS by comparing changes over time in psychiatric symptomatology: hypomanic or manic episode: Young Mania Rating Scale (YMRS score)
The Young Mania Rating Scale (YMRS) is a rating scale used to evaluate manic symptoms : there are eleven items, each item given a severity rating. Four are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale.High scores reflect a severe disorder (score range 0-60)
Time frame: At baseline, then at Day 1, Day 6, and from Day 11 to Day 14
Evolution of physiological parameters: Electrocardiography (ECG)
ECG values for waves and intervals: RR interval(seconds);P wave (milliseconds); PR (milliseconds);PR segment (milliseconds); QRS complex (milliseconds) ;ST segment (milliseconds); T wave:(milliseconds) ;QT interval (milliseconds )
Time frame: Baseline then every day from Day 1 to Day 14
Evolution of physiological parameters: blood pressure (systolic pressure and a diastolic pressure mm HG)
Blood pressure (systolic pressure and a diastolic pressure mm HG)
Time frame: Baseline then every day from Day 1 to Day 14
Evolution of physiological parameters: brething system
Brething system: breaththig freaquency ( breath per minute);
Time frame: Baseline then every day from Day 1 to Day 14
Evolution of physiological parameters: Body temperature °C
Body temperature °C
Time frame: Baseline then every day from Day 1 to Day 14
Evolution of physiological parameters: Skin conductance level (SCL)
Skin conductance level (SCL value μS)
Time frame: Baseline then every day from Day 1 to Day 14
Plan to share: No
Start is estimated for Dec 2023; primary completion for Dec 2025, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.